4.05
前日終値:
$3.49
開ける:
$3.54
24時間の取引高:
306.02K
Relative Volume:
1.55
時価総額:
$3.23M
収益:
-
当期純損益:
$-20.26M
株価収益率:
-0.4742
EPS:
-8.54
ネットキャッシュフロー:
$-8.25M
1週間 パフォーマンス:
+10.96%
1か月 パフォーマンス:
-29.69%
6か月 パフォーマンス:
-70.23%
1年 パフォーマンス:
-86.36%
Oragenics Inc Stock (OGEN) Company Profile
名前
Oragenics Inc
セクター
電話
813-286-7900
住所
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
OGEN を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
OGEN
Oragenics Inc
|
4.05 | 3.23M | 0 | -20.26M | -8.25M | -8.54 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
441.30 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
322.83 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
560.14 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
241.20 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Oragenics Inc (OGEN) 最新ニュース
Major Shareholder Odyssey Health Sells Oragenics Stock! - TipRanks
Future of Oral Probiotic Supplements | Innovations in Oral - openPR.com
Oragenics Inc. to Showcase Concussion Treatment Candidate at Major 2025 Conferences - citybuzz -
Oragenics to Present at 2025 BIO International Convention and At - GuruFocus
Oragenics, Inc. to Present ONP-002 at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium - Nasdaq
GlobeNewswire by Notified - The Manila Times
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium | OGEN Stock News - GuruFocus
Oragenics to Present at 2025 BIO International Convention and Attend 42nd Annual National Neurotrauma Society Symposium - The Manila Times
Pre-market Movers: EVGN, WINT, CARM, UNCY... - RTTNews
Oragenics to Present at 2025 BIO International Convention - GlobeNewswire
Top stock gains: US stocks posting the highest gains today - Yahoo
Rocket Lab Corporation (RKLB): A Bull Case Theory - Yahoo
Upstart Holdings, Inc. (UPST): A Bull Case Theory - Yahoo
Vireo Growth Inc. Announces Closing of Proper Brands Acquisition in Missouri - Yahoo
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers further milestone payment to Basilea - Yahoo
Pre-market Movers: STSS, SGMT, NIVF, OGEN... - RTTNews
Top Premarket Decliners - MarketScreener
Oragenics (OGEN) Resumes Trading: Key Insights for Investors | O - GuruFocus
Oragenics (OGEN) Trading Paused Due to High Volatility | OGEN St - GuruFocus
Oragenics (OGEN) Resumes Trading: Key Insights for Investors | OGEN Stock News - GuruFocus
ABB acquires Bel Products Inc. to expand enclosures portfolio in North America - Yahoo
Pre-market Movers: LYRA, INM, OGEN, VERA... - RTTNews
Oral Probiotics Supplements Gain Popularity in Digestive - openPR.com
OGEN stock touches 52-week low at $0.12 amid sharp annual decline By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.12 amid sharp annual decline - Investing.com Australia
Oragenics announces reverse stock split to begin June 3 By Investing.com - Investing.com South Africa
Pre-market Movers: SPRO, ASBP, IFRX, IMNN... - RTTNews
Oragenics (OGEN) Announces One-for-Thirty Reverse Stock Split | - GuruFocus
Oragenics announces reverse stock split to begin June 3 - Investing.com Australia
Oragenics Announces Reverse Stock Split to Boost Share Price - TipRanks
Oragenics (OGEN) Announces One-for-Thirty Reverse Stock Split | OGEN Stock News - GuruFocus
Oragenics, Inc. Announces One-for-Thirty Reverse Stock Split - GlobeNewswire
Worksport Secures ISO 9001 Certification at U.S. Factory, Unlocking Revenue & OEM Growth Pathways - The Manila Times
Oragenics Hosts Neurotrauma Medicine Webinar Presentation - TipRanks
Oragenics (NYSE:OGEN) Earns Sell Rating from Analysts at StockNews.com - Defense World
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia - GlobeNewswire
TotalEnergies sells 50% stake in Polish biogas company to HitecVision - Yahoo
Oragenics (OGEN) Gains Approval for Phase II Trial of Neuroprote - GuruFocus
Oragenics gains Australia’s nod for concussion therapy trial - Investing.com Australia
Oragenics gains Australia’s nod for concussion therapy trial By Investing.com - Investing.com Nigeria
Oragenics, Inc. Announces Approval to Initiate Phase II Concussi - GuruFocus
Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia | OGEN Stock News - GuruFocus
Oragenics, Inc. to Host Management Update Webinar on May - GlobeNewswire
Oragenics, Inc. to Host Management Update Webinar on May 20, 202 - GuruFocus
Oragenics, Inc. to Host Management Update Webinar on May 20, 2025 to Discuss Concussion Treatment Landscape, ONP-002 Clinical Program, and Strategic Vision | OGEN Stock News - GuruFocus
Oragenics, Inc. to Host Webinar on ONP-002 and Addressing Unmet Needs in Concussion Treatment - Nasdaq
CSW Industrials Announces Date for Fiscal Fourth Quarter and Full Year 2025 Earnings Release Conference Call - The Manila Times
Oragenics: Q1 Earnings Snapshot - New Haven Register
Oragenics Inc (OGEN) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):